Lung Cancer Clinical Trials in Chapel Hill, North Carolina

9 studies are recruiting for lung cancer in Chapel Hill, North Carolina right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease

   Radiation therapy is an essential treatment for tumors in the chest area, including breast, lung, esophageal, mediastinal cancers, and spine metastases. Although technical advances have reduced treatment-related illness and death, radiation exposure to the heart can still cause substantial rates of…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill, North Carolina

   Run by

   UNC Lineberger Comprehensive Cancer Center

   See if you can join NCT07685938 on ClinicalTrials.gov

2. Effects of Infusion Timing on Treatment Response in Solid Tumors

   This study evaluates whether the time of day when immunotherapy is given affects clinical outcomes. It includes patients eligible for PD-1 (programmed cell death protein 1) or PD-L1 (programmed death-ligand 1) inhibitor treatment who have either advanced or metastatic non-small cell lung cancer (NS…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of North Carolina at Chapel Hill, Department of Radiation Oncology, Chapel Hill, North Carolina

   Run by

   UNC Lineberger Comprehensive Cancer Center

   See if you can join NCT07630168 on ClinicalTrials.gov

3. PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival

   This is a hybrid decentralized, single-arm, interventional study designed to evaluate the impact of precision medicine navigation and reflexive expert review of next-generation sequencing (NGS) for patients with stage IV solid tumor malignancies (breast, lung, colorectal, and bladder cancers). The …

   Stage

   Not phased

   Ages

   18 and older

   Site

   Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina

   Run by

   UNC Lineberger Comprehensive Cancer Center

   See if you can join NCT06896162 on ClinicalTrials.gov

4. Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

   TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel. The study comprises a dose escalation phase and…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

   Locations

   18 in total

   Run by

   Tango Therapeutics, Inc.

   See if you can join NCT06922591 on ClinicalTrials.gov

5. Study of Trilaciclib and Lurbinectidin

   Lung cancer is by far the leading cause of cancer death among both men and women worldwide and the second most common cancer in terms of new cases. Small cell lung cancer (SCLC) is the deadliest form of lung cancer. The standard first-line treatment is the combination of carboplatin, etoposide, and…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill, Chapel Hill, North Carolina

   Locations

   2 in total

   Run by

   UNC Lineberger Comprehensive Cancer Center

   See if you can join NCT05578326 on ClinicalTrials.gov

6. Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring

   The goal of this study is to create a data set to add to Carevive's registry from real world clinical and patient reported data collected using an electronic care planning system (CPS) with remote symptom monitoring that is used in routine care for cancer patients on active treatment. Patients will…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Univeristy of North Carolina at Chapel Hill, Chapel Hill, North Carolina

   Locations

   7 in total

   Run by

   Carevive Systems, Inc.

   See if you can join NCT05974150 on ClinicalTrials.gov

7. Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer

   This is a phase 1, single-center, open-label study that enrolls adult subjects with extensive stage lung cancer or stage IV non-small cell lung cancer that is platinum-refractory and received PD-1 and/or PD-L1 therapy. The purpose of this study is to test the safety of using a new treatment called …

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

   Run by

   UNC Lineberger Comprehensive Cancer Center

   See if you can join NCT05620342 on ClinicalTrials.gov

8. UNC Pleural Fluid Registry

   Research with biospecimens such as blood, tissue, or body fluids can help researchers understand how the human body works. Researchers can make new tests to find diseases, understand how treatments work, or find new ways to treat a disease. The purpose of this study is to collect biospecimens for r…

   Stage

   Not phased

   Ages

   18 and older

   Site

   UNC Lingeberger Comprehensive Cancer Center, Chapel Hill, North Carolina

   Run by

   UNC Lineberger Comprehensive Cancer Center

   See if you can join NCT05620329 on ClinicalTrials.gov

9. APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

   To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring w…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of North Carolina, Chapel Hill, North Carolina

   Locations

   35 in total

   Run by

   Apollomics Inc.

   See if you can join NCT03175224 on ClinicalTrials.gov